| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.097 | 0.004 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.005 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.09 | 0.007 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.091 | 0.007 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.008 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.008 |